** Shares of drug developer Vera Therapeutics VERA.O fall 33.1% to $20.50 premarket
** Rival Otsuka's 4578.T experimental drug for a type of kidney disease showed over 50% reduction in protein in patient's urine in a late-stage trial, co says
** VERA's shares surged 60% on Monday after its experimental kidney disease drug, atacicept, helped significantly reduce harmful levels of proteins in the urine in a late-stage study
** Both companies are developing drugs to treat IgA nephropathy, which causes abnormal protein buildup in the kidneys and could eventually lead to the organ's failure
** Vera's drug atacicept reduced protein levels in patients' urine by 46%, compared with a 7% reduction with a placebo
** Up to last close, VERA down 27.6% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.